Antibody Therapy Market by Type, Application, Element Global Trends and Forecast to 2028 Global Market Insights recently introduced report on global Antibody Therapy Market report is an in-depth study providing complete analysis of the industry for the period 2022 to 2028. It provides complete overview of the industry considering all the major industry trends, market dynamics and competitive scenario. Get sample copy of this research report @ https://www.gminsights.com/requestsample/detail/5195 Following the onset of COVID-19, there was a prevalent need to identify effective treatments for the infection. To that effect, in October 2021, the FDA granted Emergency Use Authorization to several monoclonal antibody treatments as a therapy for COVID-19. Browse key industry insights spread across 160 pages with 183 market data tables & 14 figures & charts from the report, “Antibody Therapy Market Forecasts By Type (Monoclonal Antibodies [mAbs] {Oncology, Autoimmune Diseases, Infectious Diseases}, Antibody-Drug Conjugates [ADCs]), End-use (Hospitals, Specialty Centers), Industry Analysis Report, Regional, Growth Potential, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/antibody-therapy-market Moreover, in December 2021, the FDA broadened the potential use of monoclonal antibody treatment for precautionary therapy in persons at risk due to confirmed infection exposure. The approval was derived from the results of a significant clinical investigation, which discovered that the antibodies avoided symptoms in household contacts of patients who had recently tested positive. Furthermore, due to the rising demand for antibody therapy in the market, governments and leading market participants have been increasingly investing in R&D activities, which has been favorable for business growth. For instance, in January 2022, AbbVie Inc., a major biopharmaceutical company, announced that the FDA had awarded Breakthrough Therapy Designation to Teliso-V for use in patients with advanced/metastatic EGFR (epidermal growth factor receptor) wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease advanced on or after platinum-based therapy. In another instance, in February 2022, the World Health Organization (WHO) prequalified a monoclonal antibody "tocilizumab" to increase access to treatments for coronavirus. WHO has prequalified six antibody therapies previously, including the three presentations (three vials, each with a different quantity) of tocilizumab. As a result, growing prominence of © 2022 Global Market Insights Inc. All Rights Reserved
www.gminsights.com